Drug Profile
Research programme: antifungals - Cumbre Pharmaceuticals
Alternative Names: Antifungals research programme - Questcor/Cumbre PharmaceuticalsLatest Information Update: 05 Dec 2003
Price :
$50
*
At a glance
- Originator Questcor Pharmaceuticals
- Class
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 05 Dec 2003 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 05 Mar 2001 Tularik has licensed this antifungal research programme
- 05 Mar 2001 Preclinical development for Mycoses in USA (Unknown route)